Introduction: High dominant frequency (DF) sites during atrial fibrillation (AF) play an important role in the perpetuation of AF. We investigated the relationship between the DFs from intracardiac electrograms (iEGM) and the surface electrocardiogram (ECG) during AF, and the relationship between the surface ECG DF and atrial remodeling.

Methods: In 48 patients (57±11 years, 47 males, 20 paroxysmal), the V1-6 precordial leads and specific V7-9 ECG leads were recorded for 8s for an off-line analysis before AF ablation. The QRS-T complex was canceled by a template subtraction algorithm using the CEPAS™ system (Cuoretech Pty Ltd, Sydney, Australia). The iEGM DF maps, reconstructed using the Ensite NavX (St. Jude Medical, Inc., St. Paul, MN, USA) system, were simultaneously created for the right atrium and left atrium (LA) during AF.

Results: The DF in leads V8 and V9 correlated well with the DF in the LA floor (R=0.55, p<0.01; R=0.68, p<0.01, respectively), and that in V1 with the right inferior pulmonary vein (R=0.45, p=0.01). Persistent AF patients had a significantly lower DF in lead V9 (5.7±1.0Hz vs. 6.7±1.5Hz, p=0.02) than paroxysmal AF patients.

Conclusions: A frequency analysis from lead V9 reflects the LA electrical activity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jjcc.2015.06.006DOI Listing

Publication Analysis

Top Keywords

atrial fibrillation
8
ecg leads
8
frequency analysis
4
atrial
4
analysis atrial
4
fibrillation specific
4
ecg
4
specific ecg
4
leads
4
leads v7-v9
4

Similar Publications

Background: Pulsed field ablation (PFA) is gaining recognition as a nonthermal, tissue-specific technique for the treatment of atrial fibrillation (AF). The preclinical evaluation of the investigated novel PFA system from Insight Medtech Co. Ltd has demonstrated feasibility, safety, and 30-day efficacy for pulmonary vein isolation (PVI) in the swine model.

View Article and Find Full Text PDF

Very High-Power Short-Duration Ablation for Atrial Fibrillation in Adults With Congenital Heart Disease.

J Cardiovasc Electrophysiol

January 2025

Department of Electrophysiology, German Heart Center Munich, TUM University Hospital, Munich, Bavaria, Germany.

Introduction: Data regarding safety and long-term outcome of very high-power-short duration (vHPSD) ablation in adult congenital heart disease (ACHD) patients with paroxysmal or persistent atrial fibrillation (AF) are lacking.

Methods: Retrospective observational single-center study. The data of 66 consecutive ACHD patients (mean age 60 ± 12.

View Article and Find Full Text PDF

Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.

Clin Pharmacokinet

January 2025

Laboratoire de Pharmacologie et Toxicologie, Department of Pharmacology, UR 3801, Reims University Hospital, University of Reims Champagne-Ardenne, 45 rue Cognacq Jay, 51092, Reims Cedex, France.

Background And Objective: Apixaban is increasingly being used for stroke prevention in patients with end-stage kidney disease with atrial fibrillation undergoing haemodialysis, but no pharmacostatistical model is available for dosage adjustment. This study aimed to develop a population pharmacokinetic model of apixaban in these patients to characterise its dialytic clearance and determine optimal dosing regimens and discontinuation timing before surgery.

Methods: Patients received 2.

View Article and Find Full Text PDF

Bridging the Gaps in Atrial Fibrillation Management in the Emergency Department.

J Cardiovasc Dev Dis

January 2025

Department of Cardiology, Jersey General Hospital, Gloucester Street, St. Helier, Jersey JE1 3QS, UK.

Atrial fibrillation (AF) frequently presents in emergency departments (EDs), contributing significantly to adverse cardiovascular outcomes. Despite established guidelines, ED management of AF often varies, revealing important gaps in care. This review addresses specific challenges in AF management for patients in the ED, including the nuances of rate versus rhythm control, the timing of anticoagulation initiation, and patient disposition.

View Article and Find Full Text PDF

Pulsed field ablation (PFA) is a catheter-based procedure that utilizes short high voltage and short-duration electrical field pulses to induce tissue injury. The last decade has yielded significant scientific progress and quickened interest in PFA as an energy modality leading to the emergence of the clinical use of PFA technologies for the treatment of atrial fibrillation. It is generally agreed that more research is needed to improve our biophysical understanding of PFA for clinical cardiac applications as well as its potential as a potential alternative energy source to thermal ablation modalities for the treatment of other arrhythmias.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!